| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jan 3, 2017 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 1,980 | $10.46 | $20,711.00 | -7.2% | |
| Jan 3, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $55.40 | $83,100.00 | -15.8% | |
| Jan 1, 2017 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,629 | $10.49 | $17,089.19 | -2.3% | |
| Jan 1, 2017 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,810 | $10.49 | $18,987.99 | -2.1% | |
| Dec 23, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Krill Steven L. | EVP &Chief Scientific Officer | Sell | 50,505 | $76.40 | $3,858,621.81 | -100% | |
| Dec 21, 2016 | SCYX Scynexis Inc | Taglietti Marco | Chief Executive Officer | Buy | 25,000 | $3.30 | $82,500.00 | +11.1% | |
| Dec 20, 2016 | PAHC Phibro Animal Health Corp | Dagger Thomas G | SVP, GC And Corp Secretary | Sell | 1,900 | $30.03 | $57,053.00 | -100% | |
| Dec 20, 2016 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 1,792 | $30.03 | $53,821.60 | -100% | |
| Dec 19, 2016 | HROW Harrow, Inc. | Boll Andrew R. | Chief Financial Officer | Buy | 39,000 | $1.79 | $69,810.00 | +260.0% | |
| Dec 19, 2016 | HROW Harrow, Inc. | Baum Mark L66 | Chief Executive Officer | Buy | 156,000 | $1.79 | $279,240.00 | +91.9% | |
| Dec 19, 2016 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 3,250 | $7.45 | $24,212.50 | -2.6% | |
| Dec 19, 2016 | HROW Harrow, Inc. | Lindstrom Richard L Md65 | Director | Buy | 100,000 | $1.79 | $179,000.00 | New | |
| Dec 16, 2016 | LLY Eli Lilly & Co | Mahony Susan | SVP &Pres., Lilly Oncology | Sell | 20,242 | $72.65 | $1,470,615.77 | -20.3% | |
| Dec 16, 2016 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 200,000 | $72.59 | $14,518,476.60 | - | |
| Dec 16, 2016 | SCYX Scynexis Inc | Angulo Gonzalez David | Chief Medical Officer | Buy | 4,000 | $3.25 | $13,000.00 | +9.5% | |
| Dec 16, 2016 | LLY Eli Lilly & Co | Tai Jackson P | Director | Buy | 1,375 | $72.64 | $99,880.00 | +2.9% | |
| Dec 16, 2016 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 1,000 | $72.13 | $72,130.00 | -76.9% | |
| Dec 16, 2016 | LLY Eli Lilly & Co | Barnes Melissa S | Chief Eth/ Cmpl Ofcr &SVP, Erm | Sell | 2,093 | $82.23 | $172,107.39 | -20.4% | |
| Dec 16, 2016 | LLY Eli Lilly & Co | Hoover R David50 | Director | Buy | 500 | $71.85 | $35,925.00 | +50.0% | |
| Dec 16, 2016 | ALKS Alkermes Plc. | Pugh Gordon G | SVP, COO &CRO, Alkermes, Inc. | Sell | 21,458 | $57.65 | $1,236,984.75 | -34.3% | |
| Dec 15, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | EVP, Qa &Regulatory Affairs | Sell | 2,940 | $20.51 | $60,286.76 | -10.1% | |
| Dec 15, 2016 | ALKS Alkermes Plc. | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sell | 5,000 | $55.99 | $279,963.00 | -8.7% | |
| Dec 14, 2016 | BHC Bausch Health Companies Inc. | Ross Thomas W. Sr. | Director | Buy | 5,000 | $14.73 | $73,650.00 | +22.9% | |
| Dec 14, 2016 | ALKS Alkermes Plc. | Frates James M83 | SVP, Alks Inc; CFO Alks | Sell | 25,000 | $54.73 | $1,368,132.66 | -10.0% | |
| Dec 13, 2016 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 5,900 | $34.09 | $201,106.54 | -16.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.